Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hu2G10 ADC
- Development stage
- Unknown
- Lead developer
- LigaChem Biosciences, Inc.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Hu2G10 ADC (also known as LCB84) is an investigational antibody-drug conjugate (ADC) targeting the tumor-associated antigen Trop-2 (specifically the ADAM10-cleaved, activated form of Trop-2). It is composed of the humanized IgG1 monoclonal antibody Hu2G10 conjugated to the potent microtubule-disrupting agent monomethyl auristatin E (MMAE) via a plasma-stable, β-glucuronidase-cleavable linker. Developed using ConjuAll site-directed conjugation technology, Hu2G10 ADC is designed to selectively deliver its cytotoxic payload to cancer cells while sparing normal tissues that express wild-type Trop-2, thereby improving the therapeutic index. It is currently being evaluated in Phase 1/2 clinical trials for the treatment of various advanced solid tumors, including triple-negative breast cancer, non-small cell lung cancer, and pancreatic cancer.
- Other names
- Hu2G10-ADCHu-2G10-ADCHu 2G10-ADCHu2G10-MMAE ADCHu-2G10-MMAE ADCHu 2G10-MMAE ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on Hu2G10 ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hu2G10 ADC.